



**FIMECS is Named by The 2020 APAC Business Awards as
“Best Tech-Based Drug Discovery Biotech - Japan”**

Kanagawa, Japan, 21, Jan 2021 - FIMECS, Inc. (“FIMECS”) a private biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that it has been named by The 2020 APAC Business Awards organized by APAC insider as “Best Tech-Based Drug Discovery Biotech - Japan”

Please find the detail below.

APAC Insider Magazine Announces the Winners of the 2020 Business Awards: <https://www.apac-insider.com/apac-insider-magazine-announces-the-winners-of-the-2020-business-awards/>

FIMECS, Inc. Best Tech-Based Drug Discovery Biotech – Japan: [FIMECS, Inc - Japan 2020 \(apac-insider.com\)](https://www.apac-insider.com)

About FIMECS, Inc.

FIMECS, Inc. is developing a new class of drugs based on targeted protein degradation for the currently ‘undruggable’ targets in immuno-oncology and oncology areas. The company became able to discover drug candidates for inducing the degradation of disease-relevant targeted proteins by integrating proprietary E3 ligase binders and RaPPIDS™ platform. This drug discovery platform will help providing drugs to the patients all over the world through various internal and collaboration projects. <https://www.fimecs.com/eng/>

###

Contact:

FIMECS, Inc.

26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan

Tel: +81-466-32-1169

Email: info@fimecs.com